Predicting 24-Month MCI-to-Alzheimer's Conversion Using Routine Clinical Assessments Without Neuroimaging or Genetic Testing
ABSTRACT INTRODUCTION: Early identification of individuals with mild cognitive impairment (MCI) at high risk of conversion to Alzheimer's disease (AD) is essential for timely intervention. We evaluated whether routinely obtainable clinical assessments can accurately predict 24-month MC to AD conversion. METHODS: Data from 2,430 participants with MCI in the Alzheimer's Disease Neuroimaging Initiative were analyzed. XGBoost, Random Forest, and Logistic Regression models were evaluated. SHAP-based feature selection and feature ablation analyses assessed the incremental value of APOE4 genotype. RESULTS: A six-feature model incorporating age, sex, education, RAVLT Immediate Recall, MMSE, and EcogSPTotal achieved an AUC of 0.922 (95% CI, 0.911~0.933). APOE4 provided negligible additional predictive value once cognitive measures were included. The XGBoost model outperformed Clinical Dementia Rating Sum of Boxes classification. DISCUSSION: Routine cognitive assessments accurately predict 24-month MCI-to-AD progression without biomarkers, neuroimaging, or genetic testing, offering a practical, low-cost tool for clinical risk stratification.